Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports by Xin Liao, Yuxia Guo, Yali Shen, Jianwen Xiao

“…Dasatinib, a second-line tyrosine kinase inhibitor (TKI), has been widely used in chronic myeloid leukemia (CML) and Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph + B-ALL). …”
Get full text

Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

“…Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. …”
Get full text

Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature by Kirsten C. Webb, Magdalena Harasimowicz, Monica Janeczek, Jodi Speiser, James Swan, Rebecca Tung

“…Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. …”
Get full text

Exploring the association between BDNF related signaling pathways and depression: A literature review by Yuchen Fan, Xinchi Luan, Xuezhe Wang, Hongchi Li, Hongjiao Zhao, Sheng Li, Xiaoxuan Li, Zhenkang Qiu

“…At present, the pathogenesis of multiple depression is not fully clear, but its occurrence can be related to biological or environmental pathways, among which Brain-derived neurotrophic factor (BDNF) can unequivocally act on two downstream receptors, tyrosine kinase receptor (TrkB) and the p75 neurotrophin receptor (p75NTR), then affect the related signal pathways, affecting the occurrence and development of depression. …”
Get full text

A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia by Umberto Romeo, Gaspare Palaia, Paolo Junior Fantozzi, Gianluca Tenore, Daniela Bosco

“…Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a good quality of life. …”
Get full text

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma by Jeremy L. Ramdial, Luis E. Aguirre, Robert A. Ali, Ronan Swords, Mark Goodman

“…Transient cytopenias and bone marrow hypoplasia commonly occur during treatment of CML with TKIs (tyrosine kinase inhibitors). This is usually related to the eradication of CML clones that initially compose the majority of hematopoietic cells in the bone marrow at the time of diagnosis. …”
Get full text

Thyroid Mutations and Implications for Clinical Treatment by Emily S. Zhang, Joseph Scharpf

“…DTCs can have BRAF-like or RAS-like pathways of driver mutations with strong genotype–phenotype correlations, which are targetable through multikinase and tyrosine kinase inhibitors. Case studies illustrate how molecular profiling can guide clinical decisions and enhance treatment outcomes. …”
Get full text

Chronic Eosinophilic Leukemia Presenting as Cardiac Failure by Nii Boi-Doku Pepra-Ameyaw, William Kwasi Ghunney, Eugene Baafi Ampofo, Edeghonghon Olayemi

“…Good symptomatic control was achieved using hydroxyurea after which haematologic and cytogenetic remission was achieved after 12 weeks on a tyrosine kinase inhibitor. Physicians working in low resource environments should exclude clonality in patients presenting with eosinophilia and end-organ damage.…”
Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, follo... by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

“…Post-Bruton’s tyrosine kinase inhibitor failure, the prognosis remains unfavorable. …”
Get full text

“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer by ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin

“…They divided it into four molecular subtypes and proposing corresponding precision treatment strategies: canonical luminal subtype (SNF1), sensitive to endocrine therapy; immunogenic subtype (SNF2), amenable to immunotherapy; proliferative subtype (SNF3), treatable by CDK4/6 inhibitors; and receptor tyrosine kinase-driven subtype (SNF4), targetable with tyrosine kinase inhibitors. …”
Get full text

Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia by Justine Chan, Paarth Shah, Guillermo Moguel-Cobos

“…Nilotinib is a tyrosine kinase inhibitor used to treat patients with chronic myeloid leukemia (CML). …”
Get full text

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

GILT stabilizes cofilin to promote the metastasis of prostate cancer by Dunsheng Han, Zhiming Wu, Cong Zhang, Ziwei Wei, Fan Chao, Xuefeng Xie, Jinke Liu, Yufeng Song, Xiaoming Song, Dingchang Shao, Shiyu Wang, Guoxiong Xu, Gang Chen

“…Mechanistically, GILT stabilized the cofilin protein by competitively binding to cofilin with Src family tyrosine kinase (SRC), inhibiting SRC-mediated tyrosine phosphorylation of cofilin, thereby suppressing the ubiquitination pathway degradation of cofilin. …”
Get full text

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report by Yang Zhang, Ke-jie Li, Can Wang, Chang-lin Zou, Meng Su

“…Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. …”
Get full text

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA by Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

“…Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment. …”
Get full text

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma by Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini

“…After progression on first line chemotherapy, was administered neratinib, a pan‐Erb2 receptor tyrosine kinase inhibitor. Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. …”
Get full text

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs by Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng

“…In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). …”
Get full text

Regulation of Endothelial Adherens Junctions by Tyrosine Phosphorylation by Alejandro Pablo Adam

“…Inflammatory conditions promote the disassembly of the adherens junction and a loss of intercellular adhesion, creating openings or gaps in the endothelium through which small molecules diffuse and leukocytes transmigrate. Tyrosine kinase signaling has emerged as a central regulator of the inflammatory response, partly through direct phosphorylation and dephosphorylation of the adherens junction components. …”
Get full text

PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism by Hongyu Chu, Yuezhan Shan, Chengwei Jiang, Yumin Zhong, Zijing Liu, Xuedong Fang, Zhaoying Yang

“…Notably, PNMA1 has emerged as a promising therapeutic target for tyrosine kinase inhibitors, as confirmed by reduced IC50 values and molecular docking. …”
Get full text

Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models by Pallavi Sontakke, Jenny Jaques, Edo Vellenga, Jan Jacob Schuringa

“…These models not only mimic CML but also have been instrumental in uncovering various fundamental mechanisms of CML disease progression and tyrosine kinase inhibitor (TKI) resistance. With the availability of iPSC technology, it has become feasible to derive, maintain, and expand CML subclones that are at least genetically identical to those in patients. …”
Get full text